<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03685539</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0303</org_study_id>
    <secondary_id>NCI-2018-01984</secondary_id>
    <secondary_id>2018-0303</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03685539</nct_id>
  </id_info>
  <brief_title>DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis</brief_title>
  <official_title>Advanced CT Imaging Optimization for the Detection of Intracranial Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well dual energy computed tomography (DECT) works in imaging patients
      with solid organ cancer that has spread to the brain. Imaging techniques, such as DECT, may
      help find and diagnose tumor cells and find out how far the tumor cells have spread in the
      brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To optimize two major parameters of computed tomography (CT) imaging for optimal detection
      of intracranial metastatic lesions.

      Ia. Virtual monochromatic image reconstruction. Ib. Contrast bolus timing. II. To measure the
      detection accuracy of CT compared to the diagnostic standard of care gadolinium-based &quot;Gamma
      Knife (GK)&quot; protocol magnetic resonance imaging (MRI).

      OUTLINE:

      Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds
      at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best diagnostic performance of computed tomography (CT) reconstruction parameters</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>A repeated-measures analysis of variance with the Dunnett post hoc test will be used to determine the significance of the differences in the signal-to-noise (SNR) and contrast-to-noise (CNR) measurements at the optimal parameter setting, compared with all other parameter settings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of CT</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>A Bland-Altman analysis will be used to show the agreement of number of lesions between optimal parametrized CT and the one of standard of care magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Neoplasm</condition>
  <condition>Metastatic Malignant Neoplasm in the Brain</condition>
  <arm_group>
    <arm_group_label>Diagnostic (DECT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual-Energy Computed Tomography</intervention_name>
    <description>Undergo DECT</description>
    <arm_group_label>Diagnostic (DECT)</arm_group_label>
    <other_name>DECT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with pathology-proven solid organ cancer

          -  MRI of the brain with contrast, positive for two or more metastatic lesions

               -  One lesion with a single greatest diameter on contrast-enhanced MRI of 1 cm or
                  greater

          -  Planned treatment with stereotactic radiosurgery

        Exclusion Criteria:

          -  Known allergy to iodine-based contrast agents

          -  Patients with glomerular filtration rate (GFR) less than 30 or use of hemodialysis

          -  If prior nephrectomy, GFR less than 60

          -  Prior central nervous system malignancy

          -  Prior brain radiation

          -  Pregnant women are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Johnson</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason Johnson</last_name>
    <phone>713-792-8443</phone>
    <email>jjohnson12@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M. Johnson</last_name>
      <phone>713-792-8443</phone>
    </contact>
    <investigator>
      <last_name>Jason M. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

